Related Experiment Video
Updated: Oct 3, 2026

Cell-Specific Paired Interrogation of the Mouse Ovarian Epigenome and Transcriptome
Published on: February 24, 2023
Genetics of menopause-associated diseases
F Massart1, J Y Reginster, M L Brandi
1Scuola Superiore S. Anna of Pisa, Pisa, Italy.
Insights
Genetic variations increase susceptibility to postmenopausal chronic disorders like osteoporosis and Alzheimer's disease. Identifying these gene polymorphisms can help predict risk and guide personalized treatments.
Area of Science:
- Genetics
- Postmenopausal Health
- Chronic Disease Susceptibility
Background:
- Menopause affects millions globally, leading to hormonal changes.
- Postmenopausal women face increased risks of chronic conditions like cardiovascular disease, osteoporosis, and Alzheimer's dementia.
- These chronic disorders have both environmental and strong genetic components.
Purpose of the Study:
- To review current data on genetic variations contributing to susceptibility to four common postmenopausal chronic syndromes: osteoporosis (OP), osteoarthritis (OA), Alzheimer's disease (AD), and coronary artery disease (CAD).
- To explore how gene polymorphisms explain the inheritance and co-segregation of these disorders.
- To identify potential common genetic factors, particularly within the estrogen response cascade, underlying these conditions.
Main Methods:
- Review of existing clinical and genetic data.
- Analysis of candidate genes associated with OP (e.g., VDR gene), CAD (e.g., ACE gene), and other postmenopausal disorders.
- Investigation of gene polymorphisms, including those in the estrogen receptor (ERs) pathway.
Main Results:
- Genetic variations are implicated in the susceptibility to osteoporosis, osteoarthritis, Alzheimer's disease, and coronary artery disease.
- Specific genes like VDR and ACE are linked to skeletal and cardiovascular health, respectively.
- Estrogen response cascade genes are strong candidates for a shared genetic background influencing multiple postmenopausal disorders.
Conclusions:
- Genetic polymorphisms play a significant role in the development of common postmenopausal chronic diseases.
- Understanding these genetic factors can aid in identifying at-risk individuals.
- Pharmacogenetic approaches, guided by genetic profiles, may optimize treatment responsiveness in postmenopausal women.
Abstract:
Menopause is the permanent cessation of menstruation resulting from the loss of ovarian follicular activity. It is estimated that perhaps 50 million women worldwide will go into menopause annually. Atherosclerotic cardiovascular disease, osteoporotic fractures and Alzheimer's dementia are common chronic disorders after menopause, representing major health problems in most developed countries. Apart from being influenced by environmental factors, these chronic disorders recognize a strong genetic component, and there are now considerable clinic evidences that these disorders are related to low hormonal milieu of postmenopausal women. Here, we review up-to-date available data suggesting that genetic variation may contribute to higher susceptibility to four sporadic chronic syndromes such as osteoporosis (OP), osteoarthritis (OA), Alzheimer's disease (AD) and coronary artery disease (CAD). For these four syndromes candidate genes that today appear as major loci in genetic susceptibility encode for proteins specific of a given system, as the vitamin D receptor (VDR) gene for the skeleton and, therefore, OP or angiotensin converting enzyme (ACE) for the cardiovascular system and, therefore, CAD. The investigation of gene polymorphisms in various pathological conditions typical of postmenopause offer an explanation not only of their genetic inheritance but also of their co-segregation in given individuals. In this view, it may be possible to identify a common set of genes whose variants contribute to a common genetic background for these different disorders. Ideal candidates appear genes of the estrogen response cascade [i.e. estrogen receptor (ERs), enzymes involved in estrogen metabolism or co-activators and co-inhibitors]. All together this information may represent the basis both for future recognition of individuals at risk and for the pharmacogenetic driving of drug responsiveness.
Related Concept Videos
Menopause
Oogenesis
Disorders of the Female Reproductive System
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
